The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern Daylight Time), Thursday, October 28, hosted by Gary F. Burbach, president and chief executive officer, and David V. Smith, executive vice president and chief financial officer.
The teleconference can be accessed by calling (719) 325-4908, passcode 2416731. Please dial in 10-15 minutes prior the beginning of the call. The webcast will be available on the Internet at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=95989&eventID=3406099 or at http://www.thoratec.com.
A replay of the conference call will be available through Thursday, November 4, via http://www.thoratec.com, or by telephone at (719) 457-0820, passcode 2416731.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 15,000 devices implanted in patients suffering from heart failure. Additionally, its International Technidyne Corporation (ITC) Division is a leader in point-of-care blood testing and skin incision products. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's web site at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec Corporation. ITC, A-VOX Systems, AVOXimeter, HEMOCHRON, ProTime, ProTime InRhythm and IRMA are registered trademarks of International Technidyne Corporation. CentriMag is a registered trademark of Levitronix, LLC.
SOURCE Thoratec Corporation
